Aiforia Technologies

1.74 EUR

+6.48 %

2,189 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

+6.48 %
-1.30 %
-23.26 %
-30.04 %
-37.34 %
-48.15 %
-57.41 %
-
-65.57 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
58.69M EUR
Turnover
51.58K EUR
P/E (adj.) (26e)
-7.03
EV/EBIT (adj.) (26e)
-7.26
P/B (26e)
4.34
EV/S (26e)
12.98
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
08.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.5
2026

Extraordinary general meeting '26

28.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Keep these coming, more and more, although they are unfortunately slow to monetize. The wait is long, especially since all parties must proceed slowly through pilots for each cancer type separately before this becomes mainstream. *> Aiforia selected as AI partner for PROSTIA project...
4/16/2026, 9:10 AM
by Opa
34
Here are Siltanen’s comments regarding the recent news above. Aiforia announced on Thursday that it has been selected as the AI partner for the French PROSTIA project. With the agreement, the company’s prostate cancer diagnostic solution will be implemented in five new Assistance...
4/17/2026, 4:52 AM
by Sijoittaja-alokas
20
Another contract in the bag: Aiforialle sopimus yksityisen diagnostiikkalaboratorion kanssa Italiassa | Kauppalehti
7 hours ago
by NukkeNukuttaja
19
I read it, and I largely see this case the same way, even if Nuways is sometimes accused of being a bit half-baked. The most important things for me are: Strong technological and market position Conservative industry, acquired customers stay Clinical side growth 68% in 24-25, and...
8 hours ago
by Puutaheinää
16
This isn’t just “another new model,” but rather indicates that the suitability of Aiforia’s tools is being tested in new areas. Phrases like “any image analysis application” and “high-volume diagnostics” could refer to Pap smears, which would imply significant volumes, as this also...
3 hours ago
by Vino Pino
12
Yes, I believe that’s exactly the case. But as I understand it, the party that developed the model also gets a certain percentage of the revenue. In any case, it’s great if the portfolio expands rapidly like this as new users/research teams join, and as I understand it, a significant...
6 hours ago
by JusaVaan
12
“Laboratorio La Fontana aims to develop deep learning AI models for cervical cancer detection by utilizing Aiforia’s unique AI model development platform, Aiforia® Create. The AI models will be implemented in the laboratory’s clinical workflow. The goal is to also implement other...
6 hours ago
by Jekkku
10
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.